These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 33345841

  • 1. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
    Della Torre M, Enakpene C, Ravangard S, DiGiovanni L, Deyo K, Whelan A, Sutherland M, Fischer J.
    Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
    [Abstract] [Full Text] [Related]

  • 2. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML, Caritis SN, Jablonski KA, Reddy UM, Sorokin Y, Manuck T, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Peaceman AM, Mercer BM, Sciscione A, Rouse DJ, Ramin SM, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [Abstract] [Full Text] [Related]

  • 3. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S, Freedman A, Adams M, Hirsch E, Ernst LM.
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [Abstract] [Full Text] [Related]

  • 4. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW.
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [Abstract] [Full Text] [Related]

  • 5. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 6. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A, Vladutiu CJ, Dotters-Katz SK, Goodnight WH, Manuck TA.
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [Abstract] [Full Text] [Related]

  • 7. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K, Childress K, Vricella LK, Boerrigter A, Franklin BHK, Sauer M, Armbruster R, Tomlinson T.
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [Abstract] [Full Text] [Related]

  • 8. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
    Caritis SN, Costantine MM, Clark S, Stika CS, Kiley JW, Metz TD, Chauhan SP, Venkataramanan R, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers Network.
    Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
    [Abstract] [Full Text] [Related]

  • 9. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM, Lowry SA, Mikovich S, Forinash AB, Babbar S.
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [Abstract] [Full Text] [Related]

  • 10. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
    Caritis SN, Venkataramanan R, Thom E, Harper M, Klebanoff MA, Sorokin Y, Thorp JM, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Grobman WA, Mercer BM, Sciscione A, Rouse DJ, Ramin S, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network.
    Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
    [Abstract] [Full Text] [Related]

  • 11. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ.
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [Abstract] [Full Text] [Related]

  • 12. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials.
    Saccone G, Khalifeh A, Elimian A, Bahrami E, Chaman-Ara K, Bahrami MA, Berghella V.
    Ultrasound Obstet Gynecol; 2017 Mar; 49(3):315-321. PubMed ID: 27546354
    [Abstract] [Full Text] [Related]

  • 13. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC, Locci M, Saccone G, Gragnano E, Berghella V.
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [Abstract] [Full Text] [Related]

  • 14. Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J, Feghali M, Boyle A, Istwan N, Rhea D, Driggers RW.
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):881-4. PubMed ID: 23311766
    [Abstract] [Full Text] [Related]

  • 15. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC, Schoen CN, Frey H, Gimovsky AC, Springel E, Backley S, Berghella V.
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [Abstract] [Full Text] [Related]

  • 16. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB, McIntire DD, Leveno KJ.
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [Abstract] [Full Text] [Related]

  • 17. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
    Ward A, Greenberg V, Valcarcel B, Boelig RC, Al-Kouatly HB, Berghella V.
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100124. PubMed ID: 33345870
    [Abstract] [Full Text] [Related]

  • 18. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL, Walker HC, Hade EM, Iams JD.
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [Abstract] [Full Text] [Related]

  • 19. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
    Heyborne KD, Allshouse AA, Carey JC.
    Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
    [Abstract] [Full Text] [Related]

  • 20. The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women.
    Caritis SN, Dodeja P, Sharma S, Zhao W, Venkataramanan R.
    Am J Obstet Gynecol; 2024 Apr 25. PubMed ID: 38670444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.